Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Convertible Debt: 2014-2017

Historic Convertible Debt for Viking Therapeutics (VKTX) over the last 4 years, with Dec 2017 value amounting to $1.5 million.

  • Viking Therapeutics' Convertible Debt fell 59.60% to $1.5 million in Q1 2018 from the same period last year, while for Mar 2018 it was $1.5 million, marking a year-over-year decrease of 59.60%. This contributed to the annual value of $1.5 million for FY2017, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Viking Therapeutics reported Convertible Debt of $1.5 million as of FY2017, which was down 0.00% from $1.5 million recorded in FY2016.
  • Viking Therapeutics' 5-year Convertible Debt high stood at $2.2 million for FY2015, and its period low was $1.3 million during FY2014.
  • For the 3-year period, Viking Therapeutics' Convertible Debt averaged around $1.7 million, with its median value being $1.5 million (2017).
  • As far as peak fluctuations go, Viking Therapeutics' Convertible Debt spiked by 70.20% in 2015, and later crashed by 30.28% in 2016.
  • Over the past 4 years, Viking Therapeutics' Convertible Debt (Yearly) stood at $1.3 million in 2014, then surged by 70.20% to $2.2 million in 2015, then plummeted by 30.28% to $1.5 million in 2016, then remained steady at $1.5 million in 2017.